Abstract:Objective To analyze the clinical effect of low dose Tirofiban combined with dual antiplatelet therapy in the treatment of progressive cerebral infarction. Methods A total of 46 patients with progressive cerebral infarction admitted to our hospital from January to December in 2018 were selected as the research objects, and they were divided into the control group (23 cases) and the observation group (23 cases) according to the random digital table method.The control group was treated with dual antiplatelet program, and the observation group was treated with low-dose Tirofiban combined with dual antiplatelet program.The scores of national institutes of health stroke scale (NIHSS),Barthel index, hypersensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), modified Rankin scale (mRS) and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05).The NIHSS score of the observation group at 7 days after treatment was lower than that of the control group, the difference was statistically significant (P<0.05).The Barthel index of the observation group at 7 days after treatment was higher than that of the control group, the difference was statistically significant (P<0.05).The levels of hs-CRP and IL-6 in the observation group at 14 days after treatment were lower than those in the control group, the difference was statistically significant (P<0.05).The mRS score of the observation group after treatment was lower than that of the control group, and the difference was statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Low dose Tirofiban combined with dual antiplatelet regimen can achieve good therapeutic effect in the treatment of progressive cerebral infarction.